$NB
NIOCORP DEVELOPMENTS LTD Stock $nb

$nb Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000153949724000311 Filed on February 13, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.164M	$1.280M
YoY Change	102.56%	131.46%
% of Gross Profit
Research & Development	$489.0K	$828.0K
YoY Change	-65.32%	-37.13%
% of Gross Profit
Depreciation & Amortization	$1.000K	$1.000K
YoY Change	0.0%
% of Gross Profit
Operating Expenses	$5.110M	$2.917M
YoY Change	-82.5%	32.53%
Operating Profit
YoY Change
Interest Expense	$1.016M	$1.176M
YoY Change	615.49%	1334.15%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$4.225M	-$3.387M
YoY Change	-85.74%	53.4%
Income Tax
% Of Pretax Income
Net Earnings	-$4.225M	-$3.387M
YoY Change	-85.6%	53.4%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.12	-$0.10
COMMON SHARES
Basic Shares Outstanding	34.92M shares	32.91M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$194.0K	$634.0K
YoY Change	-97.28%	49.53%
Cash & Equivalents	$194.0K	$634.0K
Short-Term Investments
Other Short-Term Assets	$261.0K	$432.0K
YoY Change	171.88%	285.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$455.0K	$1.066M
YoY Change	-93.72%	98.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$17.12M	$17.13M
YoY Change	-0.33%	0.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.000K	$7.000K
YoY Change	0.0%	-22.22%
Other Assets	$35.00K	$35.00K
YoY Change	0.0%	-99.2%
Total Long-Term Assets	$17.16M	$17.17M
YoY Change	-0.33%	-19.62%
TOTAL ASSETS
Total Short-Term Assets	$455.0K	$1.066M
Total Long-Term Assets	$17.16M	$17.17M
Total Assets	$17.61M	$18.24M
YoY Change	-27.98%	-16.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.127M	$4.001M
YoY Change	149.49%	441.41%
Accrued Expenses	$434.0K	$936.0K
YoY Change	191.28%	-18.96%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$1.707M	$5.506M
YoY Change		996.81%
Total Short-Term Liabilities	$9.133M	$11.70M
YoY Change	95.23%	65.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$2.216M	$3.040M
YoY Change	-58.21%
Total Long-Term Liabilities	$2.216M	$3.040M
YoY Change	-58.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.133M	$11.70M
Total Long-Term Liabilities	$2.216M	$3.040M
Total Liabilities	$18.14M	$22.49M
YoY Change	-47.79%	217.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$161.0M	-$157.0M
YoY Change	10.26%	36.32%
Common Stock	$159.9M	$151.8M
YoY Change	18.9%	15.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.094M	-$6.082M
YoY Change
Total Liabilities & Shareholders Equity	$17.61M	$18.24M
YoY Change	-27.98%	-16.72%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	-$4.225M	-$3.387M
YoY Change	-85.6%	53.4%
Depreciation, Depletion And Amortization	$1.000K	$1.000K
YoY Change	0.0%
Cash From Operating Activities	-$991.0K	-$1.885M
YoY Change	-86.5%	-21.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	551.0K	1.428M
YoY Change	-96.11%	-371.48%
NET CHANGE
Cash From Operating Activities	-991.0K	-1.885M
Cash From Investing Activities	0.000
Cash From Financing Activities	551.0K	1.428M
Net Change In Cash	-440.0K	-457.0K
YoY Change	-106.44%	-84.19%
FREE CASH FLOW
Cash From Operating Activities	-$991.0K	-$1.885M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001512228
CY2023Q4	niobf	Other Gain OtherGain		usd
	niobf	Other Gain OtherGain		usd
CY2022Q4	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability		usd
	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability		usd
CY2023Q4	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount		usd
CY2022Q4	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount		usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount		usd
CY2023Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax		usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax		usd
CY2022Q4	us-gaap	Oci Equity Method Investment Before Tax Noncontrolling Interest OciEquityMethodInvestmentBeforeTaxNoncontrollingInterest		usd
	us-gaap	Oci Equity Method Investment Before Tax Noncontrolling Interest OciEquityMethodInvestmentBeforeTaxNoncontrollingInterest		usd
	niobf	Change In Fair Value Of Earnout Share Liability ChangeInFairValueOfEarnoutShareLiability		usd
	niobf	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	niobf	Loss On Equity Facility Shares Issued LossOnEquityFacilitySharesIssued		usd
	niobf	Foreign Currency Transaction Gain Loss Before Tax1 ForeignCurrencyTransactionGainLossBeforeTax1		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	niobf	Payments Of Deferred Transaction Costs PaymentsOfDeferredTransactionCosts		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	niobf	Deferred Transaction Costs Accrued But Not Paid DeferredTransactionCostsAccruedButNotPaid		usd
CY2023Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2022Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest		usd
CY2023Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent		usd
	niobf	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised		shares
	niobf	Class Of Warrant Or Right Exercise Price Exercised ClassOfWarrantOrRightExercisePriceExercised
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41655
	dei	Entity Registrant Name EntityRegistrantName	NioCorp Developments Ltd.
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1262185
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 South Yosemite Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 115
	dei	Entity Address City Or Town EntityAddressCityOrTown	Centennial
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80112
	dei	City Area Code CityAreaCode	(720)
	dei	Local Phone Number LocalPhoneNumber	334-7066
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34915511	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	634000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2341000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	432000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1385000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1066000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	3726000	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	35000	usd
CY2023Q2	us-gaap	Deposits Assets DepositsAssets	35000	usd
CY2023Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	7000	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	9000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	209000	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	236000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	838000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	839000	usd
CY2023Q4	us-gaap	Capitalized Costs Mineral Interests In Unproved Properties CapitalizedCostsMineralInterestsInUnprovedProperties	16085000	usd
CY2023Q2	us-gaap	Capitalized Costs Mineral Interests In Unproved Properties CapitalizedCostsMineralInterestsInUnprovedProperties	16085000	usd
CY2023Q4	us-gaap	Assets Assets	18240000	usd
CY2023Q2	us-gaap	Assets Assets	20930000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4001000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3491000	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	5506000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2093000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	95000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	71000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11695000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3562000	usd
CY2023Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	10561000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3040000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4989000	usd
CY2023Q4	niobf	Earnout Liability At Fair Value EarnoutLiabilityAtFairValue	7622000	usd
CY2023Q2	niobf	Earnout Liability At Fair Value EarnoutLiabilityAtFairValue	10521000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	135000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	164000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	22492000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	29797000	usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1830000	usd
CY2023Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	2100000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34091844	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31202131	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	151810000	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	140421000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-156981000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150477000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-911000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-911000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-6082000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-10967000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18240000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20930000	usd
CY2023Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	328000	usd
CY2022Q4	us-gaap	Labor And Related Expense LaborAndRelatedExpense	291000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	650000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	584000	usd
CY2023Q4	us-gaap	Professional Fees ProfessionalFees	952000	usd
CY2022Q4	us-gaap	Professional Fees ProfessionalFees	262000	usd
	us-gaap	Professional Fees ProfessionalFees	2139000	usd
	us-gaap	Professional Fees ProfessionalFees	426000	usd
CY2023Q4	niobf	Exploration Expenditures ExplorationExpenditures	828000	usd
CY2022Q4	niobf	Exploration Expenditures ExplorationExpenditures	1317000	usd
	niobf	Exploration Expenditures ExplorationExpenditures	1928000	usd
	niobf	Exploration Expenditures ExplorationExpenditures	2605000	usd
CY2023Q4	us-gaap	Other General Expense OtherGeneralExpense	809000	usd
CY2022Q4	us-gaap	Other General Expense OtherGeneralExpense	331000	usd
	us-gaap	Other General Expense OtherGeneralExpense	1643000	usd
	us-gaap	Other General Expense OtherGeneralExpense	668000	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	2917000	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	2201000	usd
	us-gaap	Operating Expenses OperatingExpenses	6360000	usd
	us-gaap	Operating Expenses OperatingExpenses	4283000	usd
CY2022Q4	niobf	Other Gain OtherGain	13000	usd
	niobf	Other Gain OtherGain	13000	usd
CY2023Q4	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	806000	usd
	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	2899000	usd
CY2023Q4	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-71000	usd
CY2022Q4	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-341000	usd
	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-144000	usd
	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-84000	usd
	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	1622000	usd
CY2023Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-28000	usd
CY2022Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	64000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-17000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-109000	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	1176000	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	-38000	usd
	us-gaap	Interest Expense InterestExpense	3251000	usd
	us-gaap	Interest Expense InterestExpense	220000	usd
CY2023Q4	us-gaap	Other Income OtherIncome	-1000	usd
CY2022Q4	us-gaap	Other Income OtherIncome	-2000	usd
	us-gaap	Other Income OtherIncome	-2000	usd
	us-gaap	Other Income OtherIncome	-1000	usd
CY2023Q4	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-3387000	usd
CY2022Q4	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-2429000	usd
	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-6875000	usd
	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-6306000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-101000	usd
CY2023Q4	niobf	Profit Loss1 ProfitLoss1	-3387000	usd
CY2022Q4	niobf	Profit Loss1 ProfitLoss1	-2429000	usd
	niobf	Profit Loss1 ProfitLoss1	-6774000	usd
	niobf	Profit Loss1 ProfitLoss1	-6306000	usd
CY2023Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	96000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	270000	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-3291000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-2429000	usd
	us-gaap	Profit Loss ProfitLoss	-6504000	usd
	us-gaap	Profit Loss ProfitLoss	-6306000	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3387000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2429000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6774000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6306000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	25000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	30000	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3387000	usd
CY2022Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2454000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6774000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6336000	usd
CY2023Q4	us-gaap	Oci Equity Method Investment Before Tax Noncontrolling Interest OciEquityMethodInvestmentBeforeTaxNoncontrollingInterest	96000	usd
	us-gaap	Oci Equity Method Investment Before Tax Noncontrolling Interest OciEquityMethodInvestmentBeforeTaxNoncontrollingInterest	270000	usd
CY2023Q4	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-3291000	usd
CY2022Q4	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-2454000	usd
	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-6504000	usd
	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-6336000	usd
CY2023Q4	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.09
CY2022Q4	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.09
	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.18
	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.23
CY2023Q4	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	33255557	shares
CY2022Q4	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	28056263	shares
	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	32555092	shares
	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	27924447	shares
	us-gaap	Net Income Loss NetIncomeLoss	-6774000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6306000	usd
	niobf	Change In Fair Value Of Earnout Share Liability ChangeInFairValueOfEarnoutShareLiability	-2899000	usd
	niobf	Assumption Of Private And Public Warrants AssumptionOfPrivateAndPublicWarrants	144000	usd
	niobf	Assumption Of Private And Public Warrants AssumptionOfPrivateAndPublicWarrants	84000	usd
	us-gaap	Accretion Expense AccretionExpense	3251000	usd
	us-gaap	Accretion Expense AccretionExpense	121000	usd
	niobf	Losses On Extinguishment Of Debt LossesOnExtinguishmentOfDebt	1622000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	102000	usd
	niobf	Loss On Equity Facility Shares Issued LossOnEquityFacilitySharesIssued	63000	usd
	niobf	Foreign Currency Transaction Gain Loss Before Tax1 ForeignCurrencyTransactionGainLossBeforeTax1	151000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	13000	usd
	us-gaap	Depreciation Depreciation	1000	usd
	us-gaap	Depreciation Depreciation	1000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-2000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	22000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	-4000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-6088000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-4343000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-953000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-289000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	510000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-70000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4625000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4124000	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	21000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	21000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3054000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	136000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	21000	usd
	niobf	Payments Of Deferred Transaction Costs PaymentsOfDeferredTransactionCosts	537000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2918000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-547000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-206000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1707000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4856000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2341000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5280000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	634000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	424000	usd
	niobf	Conversions Of Debt For Common Shares ConversionsOfDebtForCommonShares	8306000	usd
	niobf	Conversions Of Debt For Common Shares ConversionsOfDebtForCommonShares	1950000	usd
	niobf	Deferred Transaction Costs Accrued But Not Paid DeferredTransactionCostsAccruedButNotPaid	3800000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15412000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	300000	usd
CY2022Q4	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-25000	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-2429000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13269000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6904000	usd
CY2023Q4	niobf	Private Placement Shares May2021 PrivatePlacementSharesMay2021	1393000	usd
CY2023Q4	niobf	Shares Issued Under The Yorkville Equity Facility SharesIssuedUnderTheYorkvilleEquityFacility	244000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	2577000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-101000	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-3291000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6082000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17665000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	1950000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-21000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-30000	usd
	us-gaap	Profit Loss ProfitLoss	-6306000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13269000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10967000	usd
	niobf	Private Placement Shares May2021 PrivatePlacementSharesMay2021	2393000	usd
	niobf	Shares Issued Under The Yorkville Equity Facility SharesIssuedUnderTheYorkvilleEquityFacility	829000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	8306000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-139000	usd
	us-gaap	Profit Loss ProfitLoss	-6504000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6082000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_z6IUTakZQD61" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td id="xdx_82D_zY858vQ2PZOc" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF BUSINESS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NioCorp Developments Ltd. (“we,” “us,” “our,” “NioCorp” or the “Company”) was incorporated on February 27, 1987, under the laws of the Province of British Columbia and currently operates in <span id="xdx_902_eus-gaap--NumberOfReportableSegments_dxL_uNumber_c20230701__20231231_zfEVKmGN0Dsl" title="Number of reportable segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0613">one</span></span> reportable operating segment consisting of exploration and development of mineral deposits in North America, specifically, the Elk Creek development-stage property (the “Elk Creek Project”) located in southeastern Nebraska.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, NioCorp Technologies Ltd. (“Technologies”), a wholly owned subsidiary of the Company, was incorporated in the United Kingdom (the “UK”). The initial capital contribution in Technologies was £100 for 100 ordinary shares. Technologies was formed to provide the ability to take advantage of various business opportunities in the UK, including research and development of aluminum-scandium alloys.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These interim condensed consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and discharge of liabilities at their carrying values in the normal course of business for the foreseeable future. These financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently earns no operating revenues and will require additional capital in order to advance the Elk Creek Project to construction and commercial operation. As further discussed in Note 3, these matters raised substantial doubt about the Company’s ability to continue as a going concern, and the Company is dependent upon the generation of profits from mineral properties, obtaining additional financing and maintaining continued support from its shareholders and creditors. </span></p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80A_eus-gaap--BasisOfAccounting_zgMDpSOqC8Nh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td id="xdx_823_zERukVb2F5Hb" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BASIS OF PREPARATION</span></td> </tr></table> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znA2oQJwMEc6" style="margin-top: 0; margin-bottom: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td><td id="xdx_868_ztSiDvYEHC06" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of Preparation and Consolidation</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). The interim condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries with all significant intercompany transactions eliminated. The accounting policies followed in preparing these interim condensed consolidated financial statements are those used by the Company as set out in the audited consolidated financial statements for the year ended June 30, 2023. Certain transactions include reference to Canadian dollars (“C$”) where applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary (including normal recurring adjustments) for a fair statement of the financial position, results of operations, and cash flows at December 31, 2023, and for all periods presented, have been included in these interim condensed consolidated financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to appropriate SEC rules and regulations. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2023. The interim results are not necessarily indicative of results for the full year ending June 30, 2024, or future operating periods.</span></p> <p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zUmzYCOEPkZd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td id="xdx_861_zT7gMlRdat54" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent Accounting Standards</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Issued and Not Effective</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-06, <i>Disclosure Improvements - Codification Amendment in Response to the SEC’s Disclosure Update and Simplification Initiative</i>. The amendments in this update modify the disclosure or presentation requirements of a variety of Topics in the Accounting Standards Codification (“ASC”) in response to the SEC’s Release No. 33-10532,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Disclosure Update and Simplification Initiative, and align the ASC’s requirements with the SEC’s regulations. For entities subject to the SEC’s existing disclosure requirements, the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective. However, if by June 30, 2027, the SEC has not removed the related disclosure from its regulations, the amendments will be removed from the ASC and not become effective. Early adoption is prohibited. We are currently in the process of evaluating the impact of the amendment on our consolidated financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments will require public entities to disclose significant segment expenses that are regularly provided to the chief operating decision maker and included within segment profit and loss. The amendments are effective for the Company’s annual periods beginning July 1, 2024, and interim periods beginning July 1, 2025, with early adoption permitted, and will be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the ASU to determine its impact on the Company’s disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company’s annual periods beginning June 1, 2025, with early adoption permitted, and should be applied either prospectively or retrospectively. The Company is currently evaluating the ASU to determine its impact on the Company’s disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. Unless otherwise discussed, management believes that the impact of recently issued standards did not or will not have a material impact on the Company’s consolidated financial statements upon adoption.</span></p> <p id="xdx_847_eus-gaap--UseOfEstimates_zFcnEKIvdH09" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td id="xdx_86D_zeoR1Z2hMXI4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Estimates</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the carrying value of long-term assets, deferred income tax assets and related valuations, liabilities related to the Earnout Shares, Private Warrants, and Contingent Consent Warrants (each, as defined below), and share-based compensation. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected.</span></p> <p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z4NC3Kue8iv5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_863_z2v5BsP9UDa">Basic and Diluted Earnings per Share</span></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zPXBSgYSos9l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the weighted average method to determine the impact of changes in a participating security on the calculation of loss per share. <span id="xdx_8BB_zXon4ePlpwZ5">The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common shareholders:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="6" style="text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0">For the Three Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="6" style="text-align: center; vertical-align: bottom"><p style="margin-top: 0; margin-bottom: 0">For the Six Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">2023</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; vertical-align: bottom">2022</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right; vertical-align: bottom">2023</td><td style="text-align: center; vertical-align: bottom"> </td><td style="text-align: center; vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right; vertical-align: bottom">2022</td><td style="text-align: center; vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify; padding-left: 0.25in; text-indent: -0.125in">Net loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20231001__20231231_z5fxb6oKejDb" style="width: 9%; text-align: right" title="Net loss">3,387</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20221001__20221231_z4QrVarF7lyd" style="width: 9%; text-align: right" title="Net loss">2,429</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20230701__20231231_zm4c5ZjAcVX7" style="width: 9%; text-align: right" title="Net loss">6,774</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20220701__20221231_zFVLjMVVfHBa" style="width: 9%; text-align: right" title="Net loss">6,306</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 0.25in; text-indent: -0.125in">Adjust: Net loss attributable to noncontrolling interest</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_c20231001__20231231_zRAZR7RFXPf3" style="border-bottom: Black 1pt solid; text-align: right" title="Adjust: net loss attributable to noncontrolling interest">(96</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_c20221001__20221231_z21dcrD0MyA5" style="border-bottom: Black 1pt solid; text-align: right" title="Adjust: net loss attributable to noncontrolling interest"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_c20230701__20231231_zDpiyr74ONed" style="border-bottom: Black 1pt solid; text-align: right" title="Adjust: net loss attributable to noncontrolling interest">(270</td><td style="text-align: left; padding-bottom: 1pt">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_c20220701__20221231_zP36fucSMpF5" style="border-bottom: Black 1pt solid; text-align: right" title="Adjust: net loss attributable to noncontrolling interest"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 0.25in; text-indent: -0.125in">Net loss available to participating securities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20231001__20231231_zvcGQiMmydf8" style="text-align: right" title="Net loss available to participating securities">3,291</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20221001__20221231_zdhxyfL4KVJd" style="text-align: right" title="Net loss available to participating securities">2,429</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20231231_z3MbB4dRyT72" style="text-align: right" title="Net loss available to participating securities">6,504</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220701__20221231_zQ0vP8vzNjIb" style="text-align: right" title="Net loss available to participating securities">6,306</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 0.25in; text-indent: -0.125in">Net loss attributable to vested shares of ECRC Class B common stock</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_pn3n3_c20231001__20231231_zqomIYHFxIba" style="border-bottom: Black 1pt solid; text-align: right" title="Net loss attributable to vested shares of ECRC Class B common stock">(321</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_pn3n3_c20221001__20221231_z7PzFOCFRsQf" style="border-bottom: Black 1pt solid; text-align: right" title="Net loss attributable to vested shares of ECRC Class B common stock"><span style="-sec-ix-hidden: xdx2ixbrl0667">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_pn3n3_c20230701__20231231_zX1uLjdIg9a6" style="border-bottom: Black 1pt solid; text-align: right" title="Net loss attributable to vested shares of ECRC Class B common stock">(580</td><td style="text-align: left; padding-bottom: 1pt">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_pn3n3_c20220701__20221231_zxrTsc3IvcHc" style="border-bottom: Black 1pt solid; text-align: right" title="Net loss attributable to vested shares of ECRC Class B common stock"><span style="-sec-ix-hidden: xdx2ixbrl0671">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 0.25in; text-indent: -0.125in">Net loss attributed to common shareholders - basic and diluted</td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_pn3n3_c20231001__20231231_zDEz7Cx5jYR4" style="border-bottom: Black 2.5pt solid; text-align: right" title="Net loss attributed to common shareholders - basic and diluted">2,970</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_pn3n3_c20221001__20221231_zmGkS8l4avmd" style="border-bottom: Black 2.5pt solid; text-align: right" title="Net loss attributed to common shareholders - basic and diluted">2,429</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_pn3n3_c20230701__20231231_znhjMN4CToa6" style="border-bottom: Black 2.5pt solid; text-align: right" title="Net loss attributed to common shareholders - basic and diluted">5,924</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_pn3n3_c20220701__20221231_z3UsAKrT79bb" style="border-bottom: Black 2.5pt solid; text-align: right" title="Net loss attributed to common shareholders - basic and diluted">6,306</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 0.25in; text-indent: -0.125in">Weighted average shares outstanding – basic and diluted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_c20231001__20231231_zOr8lYCpFw1a" style="text-align: right" title="Weighted average shares outstanding basic and diluted">33,255,557</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_c20221001__20221231_zzVK9UyG5cu1" style="text-align: right" title="Weighted average shares outstanding basic and diluted">28,056,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_c20230701__20231231_zYzn7Yk6XA7k" style="text-align: right" title="Weighted average shares outstanding basic and diluted">32,555,092</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_c20220701__20221231_zUOUSE70qMF9" style="text-align: right" title="Weighted average shares outstanding basic and diluted">27,924,447</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 0.25in; text-indent: -0.125in">Loss per Common Share outstanding – basic and diluted</td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left">$</td><td id="xdx_985_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20231001__20231231_z0AmaaVjVgl7" style="border-bottom: Black 2.5pt solid; text-align: right" title="Loss per common share outstanding basic and diluted">0.09</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20221001__20221231_z6vPFhXlKU38" style="border-bottom: Black 2.5pt solid; text-align: right" title="Loss per common share outstanding basic and diluted">0.09</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left">$</td><td id="xdx_987_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20230701__20231231_zeyQ5aHbtHPg" style="border-bottom: Black 2.5pt solid; text-align: right" title="Loss per common share outstanding basic and diluted">0.18</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20220701__20221231_z0mtKFqaOpKb" style="border-bottom: Black 2.5pt solid; text-align: right" title="Loss per common share outstanding basic and diluted">0.23</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_z37Jb7SDqxIb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following common shares, no par value, of the Company (“Common Shares”) underlying options to purchase Common Shares (“Options”), Common Share purchase warrants (“Warrants”), and outstanding convertible debt were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation for the three- and six-month periods indicated below.</span></p> <p id="xdx_892_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zHmt06DfStwf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z5CL5vWLLzX4" style="display: none; visibility: hidden">Schedule of excluded from the dilutive securities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.4in; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="6" style="text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Three and Six Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31,</p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">Excluded potentially dilutive securities <sup id="xdx_F64_zeIFnBcdMV2j">(1)(2)</sup>:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">2023</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">2022</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 54%">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--IncrementalCommonSharesAttributableToWrittenPutOptions_pid_uShares_c20231001__20231231_fKDEpKDIp_znG91jPStOQ4" style="width: 10%; text-align: right" title="Options"><span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToWrittenPutOptions_pid_uShares_c20230701__20231231_fKDEpKDIp_ztTmh1qT4bv">938,000</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--IncrementalCommonSharesAttributableToWrittenPutOptions_pid_uShares_c20221001__20221231_fKDEpKDIp_zghZmedpE8Q6" style="width: 10%; text-align: right" title="Options"><span id="xdx_904_eus-gaap--IncrementalCommonSharesAttributableToWrittenPutOptions_pid_uShares_c20220701__20221231_fKDEpKDIp_zsNCm3CNp41i">996,000</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_uShares_c20231001__20231231_fKDEpKDIp_zSFvVXSjSL4b" style="text-align: right" title="Warrants"><span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_uShares_c20230701__20231231_fKDEpKDIp_zuGw5gepKnLk">19,032,421</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_uShares_c20221001__20221231_fKDEpKDIp_zNkbkxtVhr8g" style="text-align: right" title="Warrants"><span id="xdx_90D_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_uShares_c20220701__20221231_fKDEpKDIp_zmILO60fo6x">1,801,624</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_uShares_c20231001__20231231_fKDEpKDIp_zTzaFIyRFtj6" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible debt"><span id="xdx_908_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_uShares_c20230701__20231231_fKDEpKDIp_zdxudHNnHmd6">2,089,860</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_uShares_c20221001__20221231_fKDEpKDIp_zZDRTBkA9GSh" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible debt"><span id="xdx_906_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_uShares_c20220701__20221231_fKDEpKDIp_z6h0OUulhyq9">81,600</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total potential dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left"></td><td id="xdx_985_eus-gaap--DilutiveSecurities_c20231001__20231231_fKDEpKDIp_za3k8Rh9WMHd" style="border-bottom: Black 2.5pt solid; text-align: right" title="Total potentially dilutive securities"><span id="xdx_900_eus-gaap--DilutiveSecurities_c20230701__20231231_fKDEpKDIp_zk8pAm5sB28c">22,060,281</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt solid; text-align: left"></td><td id="xdx_98B_eus-gaap--DilutiveSecurities_c20221001__20221231_fKDEpKDIp_zyRytWdRqXg2" style="border-bottom: Black 2.5pt solid; text-align: right" title="Total potentially dilutive securities"><span id="xdx_90F_eus-gaap--DilutiveSecurities_c20220701__20221231_fKDEpKDIp_ztTCmyspXdQg">2,879,224</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.4in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span id="xdx_F01_zjWJHEvU3rib" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: justify"><span id="xdx_F1F_zvrNcZUkyoa6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of the period end. Such amounts have not been adjusted for the treasury stock method or weighted average outstanding calculations as required if the securities were dilutive.</span></td></tr> </table> <p style="margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="width: 0.4in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F05_ziFlFW4hRdZb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zUx7pSLSGTpd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout Shares are excluded as the vesting terms were not met as of the end of the reporting period.</span></td></tr> </table> <p id="xdx_8AC_zCgm0tShj2R3" style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_852_zeWZWZzdzZBj" style="margin-top: 0; margin-bottom: 0; text-align: justify"></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zFcnEKIvdH09" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td><td id="xdx_86D_zeoR1Z2hMXI4" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Estimates</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the carrying value of long-term assets, deferred income tax assets and related valuations, liabilities related to the Earnout Shares, Private Warrants, and Contingent Consent Warrants (each, as defined below), and share-based compensation. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected.</span></p>
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-3387000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2429000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6774000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6306000	usd
CY2023Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	96000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	270000	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3291000	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2429000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6504000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	6306000	usd
CY2023Q4	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-321000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-580000	usd
CY2023Q4	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	2970000	usd
CY2022Q4	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	2429000	usd
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	5924000	usd
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	6306000	usd
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33255557	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28056263	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32555092	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27924447	shares
CY2023Q4	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.09
CY2022Q4	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.09
	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.18
	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	0.23
CY2023Q4	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	938000	shares
	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	938000	shares
CY2022Q4	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	996000	shares
	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	996000	shares
CY2023Q4	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	19032421	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	19032421	shares
CY2022Q4	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1801624	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1801624	shares
CY2023Q4	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2089860	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2089860	shares
CY2022Q4	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	81600	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	81600	shares
CY2023Q4	us-gaap	Dilutive Securities DilutiveSecurities	22060281000	usd
	us-gaap	Dilutive Securities DilutiveSecurities	22060281000	usd
CY2022Q4	us-gaap	Dilutive Securities DilutiveSecurities	2879224000	usd
	us-gaap	Dilutive Securities DilutiveSecurities	2879224000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6774000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6306000	usd
CY2023Q4	us-gaap	Investment Company Distributable Earnings Loss Accumulated Capital Loss Carryforward InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward	10629000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-156981000	usd
	niobf	Cash And Cash Equivalents At Carrying Value1 CashAndCashEquivalentsAtCarryingValue1	634000	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	61796000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3160000	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1990000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	765000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1324000	usd
CY2023Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	101000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	48000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	48000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	28000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	28000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4001000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3491000	usd
CY2023Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	273000	usd
CY2023Q3	us-gaap	Stock Issued1 StockIssued1	314000	usd
CY2023Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer	41000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75000	shares
CY2023Q4	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	234000	usd
CY2023Q2	us-gaap	Convertible Debt ConvertibleDebt	10561000	usd
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	3251000	usd
	niobf	Principal And Accrued Interest Converted PrincipalAndAccruedInterestConverted	8306000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	5506000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	494000	usd
CY2023Q4	us-gaap	Convertible Subordinated Debt ConvertibleSubordinatedDebt	6000000	usd
CY2023Q3	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	962000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1241000	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70000	shares
CY2023Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	259000	usd
CY2023Q3	us-gaap	Stock Issued1 StockIssued1	271000	usd
CY2023Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer	12000	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75000	shares
CY2023Q4	us-gaap	Stock Issued1 StockIssued1	244000	usd
CY2023Q4	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer	10000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1541500	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.64
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7800	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	595700	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.37
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	938000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.12
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	938000	shares
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	938000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18816304	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.98
	niobf	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	-663432	shares
	niobf	Class Of Warrant Or Right Exercise Price Granted ClassOfWarrantOrRightExercisePriceGranted	3.94
	niobf	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	447315	shares
	niobf	Class Of Warrant Or Right Exercise Price Expired ClassOfWarrantOrRightExercisePriceExpired	8.94
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	19032421	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.78
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	19032421	shares
	us-gaap	Business Combination Contingent Consideration Arrangements Description BusinessCombinationContingentConsiderationArrangementsDescription	As consideration for entering into the previously publicly disclosed Waiver and Consent Agreement, dated September 25, 2022 (the “Lind Consent”), between the Company and Lind Global Asset Management III, LLC (“Lind”), Lind received, amongst other things, the right to receive additional Warrants (the “Contingent Consent Warrants”) if on September 17, 2024, the closing trading price of the Common Shares on the TSX or such other stock exchange on which such shares may then be listed, is less than C$10.00, subject to adjustments. The number of Contingent Consent Warrants to be issued, if any, is based on the Canadian dollar equivalent (based on the then current Canadian to US dollar exchange rate as reported by Bloomberg, LP) of $5,000 divided by the five-day volume weighted average price of the Common Shares on the date of issuance
CY2023Q4	us-gaap	Exploration Expense ExplorationExpense	828000	usd
CY2022Q4	us-gaap	Exploration Expense ExplorationExpense	1317000	usd
	us-gaap	Exploration Expense ExplorationExpense	1928000	usd
	us-gaap	Exploration Expense ExplorationExpense	2605000	usd
CY2023Q4	niobf	Fixed Rent Expense FixedRentExpense	23000	usd
CY2022Q4	niobf	Fixed Rent Expense FixedRentExpense	23000	usd
	niobf	Fixed Rent Expense FixedRentExpense	45000	usd
	niobf	Fixed Rent Expense FixedRentExpense	43000	usd
CY2023Q4	us-gaap	Variable Lease Cost VariableLeaseCost	3000	usd
CY2022Q4	us-gaap	Variable Lease Cost VariableLeaseCost	3000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	7000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	5000	usd
CY2023Q4	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	usd
CY2022Q4	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	5000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	9000	usd
CY2023Q4	us-gaap	Sublease Income SubleaseIncome	10000	usd
CY2022Q4	us-gaap	Sublease Income SubleaseIncome	12000	usd
	us-gaap	Sublease Income SubleaseIncome	16000	usd
	us-gaap	Sublease Income SubleaseIncome	15000	usd
CY2023Q4	us-gaap	Lease Cost LeaseCost	18000	usd
CY2022Q4	us-gaap	Lease Cost LeaseCost	17000	usd
	us-gaap	Lease Cost LeaseCost	41000	usd
	us-gaap	Lease Cost LeaseCost	42000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	291000	usd
CY2023Q4	niobf	Less Amount Of Payments Representing Interest LessAmountOfPaymentsRepresentingInterest	-61000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	230000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	95000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	135000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	634000	usd
CY2023Q4	niobf	Available For Sale Securities Equity Securities Other AvailableForSaleSecuritiesEquitySecuritiesOther	7000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	641000	usd
CY2023Q4	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	7622000	usd
CY2023Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5133000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	12755000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2341000	usd
CY2023Q2	niobf	Available For Sale Securities Equity Securities Other AvailableForSaleSecuritiesEquitySecuritiesOther	9000	usd
CY2023Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2350000	usd
CY2023Q2	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	10521000	usd
CY2023Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	4989000	usd
CY2023Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	15510000	usd

Files In Submission

Name	View Source	Status
0001539497-24-000311-index-headers.html	Edgar Link	pending
0001539497-24-000311-index.html	Edgar Link	pending
0001539497-24-000311.txt	Edgar Link	pending
0001539497-24-000311-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
n2574_x189-10q.htm	Edgar Link	pending
n2574_x189-img001.jpg	Edgar Link	pending
n2574_x189exh31-1.htm	Edgar Link	pending
n2574_x189exh31-2.htm	Edgar Link	pending
n2574_x189exh32-1.htm	Edgar Link	pending
n2574_x189exh32-2.htm	Edgar Link	pending
niobf-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
niobf-20231231_cal.xml	Edgar Link	unprocessable
niobf-20231231_def.xml	Edgar Link	unprocessable
niobf-20231231_lab.xml	Edgar Link	unprocessable
niobf-20231231_pre.xml	Edgar Link	unprocessable
n2574_x189-10q_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NB
NIOCORP DEVELOPMENTS LTD Stock $nb

2024 Q1 Form 10-Q Financial Statement

#000153949724000311 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NB NIOCORP DEVELOPMENTS LTD Stock $nb

2024 Q1 Form 10-Q Financial Statement

#000153949724000311 Filed on February 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NB
NIOCORP DEVELOPMENTS LTD Stock $nb